Ionis to present at RBC Capital Markets Global Healthcare Conference
Get Alerts IONS Hot Sheet
Join SI Premium – FREE
CARLSBAD, Calif., May 12, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022.
A live webcast and additional information about this presentation can be accessed on the Investors & Media section of the Ionis website at www.ionispharma.com. A replay will be available on the Ionis website within 48 hours of each event.
About Ionis Pharmaceuticals, Inc.For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-to-present-at-rbc-capital-markets-global-healthcare-conference-301545318.html
SOURCE Ionis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pinetree Capital Ltd Announces Unaudited Financial Results for the Period Ended March 31, 2024
- HRT Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the HireRight Holdings Corp. Class Action
- ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Shoals Technologies Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SHLS
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
RBC Capital, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!